POSEIDON

NCT03164616 📎

Regimen

Experimental: durvalumab ± tremelimumab + chemo
Control: chemo

Population

1L metastatic NSCLC

Key finding

durva+treme+chemo vs chemo mOS 14.0 vs 11.7 mo HR 0.77 (0.65-0.92); durva+chemo OS HR 0.86

Source: PMID 36327426

Timeline

Enrollment start: 2017-06-01 📎

Guideline citations

NCCN NSCLC Version 5.2026 (p.113)